- Home
- IMNN vs INDP Comparison
IMNN vs INDP Comparison
Compare IMNN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- INDP
- Stock Information
- Founded
- IMNN 1982
- INDP 2000
- Country
- IMNN United States
- INDP United States
- Employees
- IMNN N/A
- INDP N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- INDP Health Care
- Exchange
- IMNN Nasdaq
- INDP Nasdaq
- Market Cap
- IMNN 12.2M
- INDP 10.2M
- IPO Year
- IMNN 1985
- INDP N/A
- Fundamental
- Price
- IMNN $0.84
- INDP $0.94
- Analyst Decision
- IMNN Strong Buy
- INDP Strong Buy
- Analyst Count
- IMNN 2
- INDP 2
- Target Price
- IMNN $20.50
- INDP $8.50
- AVG Volume (30 Days)
- IMNN 191.0K
- INDP 24.7K
- Earning Date
- IMNN 11-07-2024
- INDP 11-12-2024
- Dividend Yield
- IMNN N/A
- INDP N/A
- EPS Growth
- IMNN N/A
- INDP N/A
- EPS
- IMNN N/A
- INDP N/A
- Revenue
- IMNN N/A
- INDP N/A
- Revenue This Year
- IMNN N/A
- INDP N/A
- Revenue Next Year
- IMNN N/A
- INDP N/A
- P/E Ratio
- IMNN N/A
- INDP N/A
- Revenue Growth
- IMNN N/A
- INDP N/A
- 52 Week Low
- IMNN $0.48
- INDP $0.84
- 52 Week High
- IMNN $3.65
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- IMNN 50.04
- INDP 34.68
- Support Level
- IMNN $0.80
- INDP $0.94
- Resistance Level
- IMNN $0.88
- INDP $1.06
- Average True Range (ATR)
- IMNN 0.05
- INDP 0.05
- MACD
- IMNN 0.01
- INDP 0.00
- Stochastic Oscillator
- IMNN 41.75
- INDP 0.00
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.